Related Experiment Videos
CpG oligodeoxynucleotide enhances tumor response to radiation
Luka Milas1, Kathryn A Mason, Hisanori Ariga
1Department of Experimental Radiation Oncology-66, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA. lmilas@mdanderson.org
Cancer Research
|August 4, 2004
Summary
CpG oligodeoxynucleotides (ODNs) significantly enhance tumor response to radiotherapy by boosting immune cell activity. This combination therapy improved tumor growth delay and cure rates in mice, showing potential for clinical applications.
Area of Science:
- Immunology
- Oncology
- Radiotherapy
Background:
- CpG oligodeoxynucleotides (ODNs) are synthetic DNA with unmethylated cytosine-guanine motifs.
- CpG ODNs activate immune cells via Toll-like receptor 9, inducing cytokines and T-cell responses.
- CpG ODNs have demonstrated efficacy in improving chemotherapy outcomes.
Purpose of the Study:
- To investigate the potential of CpG ODNs to enhance tumor response to radiotherapy.
- To evaluate the combined effects of CpG ODNs and radiation on tumor growth and cure rates.
Main Methods:
- Utilized an immunogenic mouse tumor model (FSa).
- Assessed tumor response by measuring tumor growth delay and tumor cure rate (TCD(50)).
- Administered CpG ODN peritumorally alongside single-dose radiation to established tumors.
Main Results:
- CpG ODN alone had minimal effect on tumor growth.
- CpG ODN dramatically enhanced radiation-induced tumor growth delay (2.58-2.65 fold).
- CpG ODN significantly improved tumor radiocurability, reducing TCD(50) by 1.93 fold.
- Histological analysis revealed increased necrosis and inflammatory cell infiltration in combined treatment groups.
Conclusions:
- CpG ODNs are potent enhancers of tumor radioresponse.
- The observed enhancement is dependent on an intact host immune system.
- CpG ODNs hold significant potential for improving clinical radiotherapy outcomes.